A retrospective study assessing the efficacy of innovator ranibizumab vs. biosimilar ranibizumab in eyes with diabetic macular edema (DME) in an Indian population
Latest Information Update: 01 Feb 2022
At a glance
- Drugs Ranibizumab (Primary) ; Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
Most Recent Events
- 01 Feb 2022 New trial record
- 24 Jan 2022 Results published in the Ophthalmology and Therapy